Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hoadley

Showing results (131-140 of 191) with videos related to

Pageof 20
Sort By:
Breast Cancer Research : BCR|December 5, 2024
Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situMarija Debeljak, Soonweng Cho, Bradley M Downs, et al.
Journal of the National Cancer Institute|January 24, 2018
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast CancerLinda S Lindström, Christina Yau, Kamila Czene, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Cell|April 7, 2018
Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationTathiane M Malta, Artem Sokolov, Andrew J Gentles, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Nature Genetics|September 8, 2015
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaRichard A Moffitt, Raoud Marayati, Elizabeth L Flate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2018
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast CancerMaki Tanioka, Cheng Fan, Joel S Parker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Pageof 20

Showing results (131-140 of 191) with videos related to

Sort By:
Pageof 20
Breast Cancer Research : BCR|December 5, 2024
Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situMarija Debeljak, Soonweng Cho, Bradley M Downs, et al.
Journal of the National Cancer Institute|January 24, 2018
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast CancerLinda S Lindström, Christina Yau, Kamila Czene, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Cell|April 7, 2018
Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationTathiane M Malta, Artem Sokolov, Andrew J Gentles, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Nature Genetics|September 8, 2015
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaRichard A Moffitt, Raoud Marayati, Elizabeth L Flate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2018
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast CancerMaki Tanioka, Cheng Fan, Joel S Parker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Pageof 20